Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn’s Disease Activity: A Prospective Cross-Sectional Study
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf025 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Natsuki Ishida und 11 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. Hauptthemen laut MEDLINE: Crohn Disease, Biomarkers. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
The goal of treatment for Crohn’s disease (CD) is to achieve mucosal or transmural healing, and biomarker measurements are useful in monitoring disease activity and guiding treatment. This study aimed to investigate the utility of a new urinary biomarker, prostaglandin E-major urinary metabolite (PGE-MUM), in assessing CD activity.
Methods
The study involved 87 patients with CD who underwent endoscopic examination and measurements of 4 biomarkers: Prostaglandin E-major urinary metabolite, fecal calprotectin (FC), leucine-rich α2 glycoprotein (LRG), and C-reactive protein (CRP). Endoscopic activity was assessed by the Simple Endoscopic Score for Crohn’s Disease (SES-CD). Correlations between the CD activity index (CDAI) and SES-CD with the 4 biomarkers were analyzed, and receiver-operating characteristic (ROC) analyses were performed to predict SES-CD ≧ 3.
Results
All 4 biomarkers showed significant correlations with both CDAI and SES-CD. The cutoff (area under the curve [AUC]) values for predicting SES-CD ≥ 3 were as follows: PGE-MUM, 25.2 µg/g Cr (0.800); FC, 257 mg/kg (0.816); LRG, 11.8 µg/mL (0.748); and CRP, 0.22 mg/dL (0.656). Subgroup analysis revealed significant correlations between PGE-MUM and SES-CD in both the L1 (small intestine only) and L2 + L3 (including large intestine) groups, with correlation coefficients of 0.654 and 0.586, respectively. In the L1 group, ROC analysis revealed that, among the 4 biomarkers, PGE-MUM had the highest AUC for predicting SES-CD ≥ 3, with a cutoff (AUC) of 33.1 µg/g Cr (0.861).
Conclusions
PGE-MUM is a biomarker that can reflect endoscopic activity in patients with CD and may be particularly useful in small intestinal lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
- Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
- Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
ORCID-Profile: Ken Sugimoto
Zitieren
APA
Ishida, N., Tamura, S., Takebe, T., Takahashi, K., Asai, Y., Matsuura, T., Yamade, M., Iwaizumi, M., Hamaya, Y., Yamada, T., Osawa, S., & Sugimoto, K. (2025). Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn’s Disease Activity: A Prospective Cross-Sectional Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf025
Vancouver
Ishida N, Tamura S, Takebe T, Takahashi K, Asai Y, Matsuura T, et al. Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn’s Disease Activity: A Prospective Cross-Sectional Study. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf025
BibTeX
@article{Ishida2025,
author = {Ishida, Natsuki and Tamura, Satoshi and Takebe, Tomohiro and Takahashi, Kenichi and Asai, Yusuke and Matsuura, Tomoharu and Yamade, Mihoko and Iwaizumi, Moriya and Hamaya, Yasushi and Yamada, Takanori and Osawa, Satoshi and Sugimoto, Ken},
title = {Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn’s Disease Activity: A Prospective Cross-Sectional Study},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf025}
}
EUVIMED